Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Ref Type||Journal Article|
|Authors||Shirai CL, White BS, Tripathi M, Tapia R, Ley JN, Ndonwi M, Kim S, Shao J, Carver A, Saez B, Fulton RS, Fronick C, O'Laughlin M, Lagisetti C, Webb TR, Graubert TA, Walter MJ|
|Title||Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome.|
|Date||2017 01 09|
|Abstract Text||Somatic mutations in spliceosome genes are detectable in ∼50% of patients with myelodysplastic syndromes (MDS). We hypothesize that cells harbouring spliceosome gene mutations have increased sensitivity to pharmacological perturbation of the spliceosome. We focus on mutant U2AF1 and utilize sudemycin compounds that modulate pre-mRNA splicing. We find that haematopoietic cells expressing mutant U2AF1(S34F), including primary patient cells, have an increased sensitivity to in vitro sudemycin treatment relative to controls. In vivo sudemycin treatment of U2AF1(S34F) transgenic mice alters splicing and reverts haematopoietic progenitor cell expansion induced by mutant U2AF1 expression. The splicing effects of sudemycin and U2AF1(S34F) can be cumulative in cells exposed to both perturbations-drug and mutation-compared with cells exposed to either alone. These cumulative effects may result in downstream phenotypic consequences in sudemycin-treated mutant cells. Taken together, these data suggest a potential for treating haematological cancers harbouring U2AF1 mutations with pre-mRNA splicing modulators like sudemycins.|
|Molecular Profile||Treatment Approach|
|Gene Name||Source||Synonyms||Protein Domains||Gene Description||Gene Role|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Sudemycin D1||Sudemycin D1 is a synthetic compound that targets spilcesome function, therefore exhibits antitumor activity (PMID: 28067246).|
|Sudemycin D6||Sudemycin D6 is a synthetic compound that targets spilcesome function, therefore exhibits antitumor activity (PMID: 28067246).|
|Gene||Variant||Impact||Protein Effect||Variant Description||Associated with drug Resistance|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|U2AF1 S34F||acute myeloid leukemia||sensitive||Sudemycin D6||Preclinical||Actionable||In a preclinical study, Sudemycin D6 treatment induced cell cycle arrest and growth inhibition in acute myeloid leukemia cell lines expressing U2AF1 S34F in culture, and inhibited progenitor cells expansion in transgenic mouse models (PMID: 28067246).||28067246|
|U2AF1 S34F||acute myeloid leukemia||sensitive||E7107||Preclinical - Patient cell culture||Actionable||In a preclinical study, patient-derived acute myeloid leukemia cells harboring U2AF1 S34F were sensitive to E7107 in cell culture (PMID: 28067246).||28067246|